5-Gene-Multiplex 0.1% AF cfDNA in Plasma
The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma from SensID is a crucial reference material for liquid biopsy assays, used in both research and clinical diagnostics. It targets key mutations in five genes-AKT1, BRAF, KRAS, PIK3CA, and ERBB2-which are associated with cancer types like lung, breast, colorectal, and melanoma. This product contains a 0.1% allelic frequency of these mutations, making it an essential positive control for digital PCR and next-generation sequencing (NGS). It supports the validation and development of sequencing protocols and PCR methods, helping to determine detection limits and ensuring reliable variant calling. The mutations in the product include: AKT1 (p.E17K), BRAF (p.V600E), KRAS (multiple variants), PIK3CA (p.E545K, p.H1047R), ERBB2 (p.Y772_A775dup). These mutations are critical for guiding personalized therapies, including targeted treatments for BRAF, KRAS, PIK3CA, and AKT1 mutations. The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product plays an integral role in advancing cancer diagnostics and improving the accuracy of liquid biopsy testing, facilitating the development of more effective cancer treatments.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma from SensID is a crucial reference material for liquid biopsy assays, used in both research and clinical diagnostics. It targets key mutations in five genes-AKT1, BRAF, KRAS, PIK3CA, and ERBB2-which are associated with cancer types like lung, breast, colorectal, and melanoma.
This product contains a 0.1% allelic frequency of these mutations, making it an essential positive control for digital PCR and next-generation sequencing (NGS). It supports the validation and development of sequencing protocols and PCR methods, helping to determine detection limits and ensuring reliable variant calling. The mutations in the product include:
- AKT1 (p.E17K),
- BRAF (p.V600E),
- KRAS (multiple variants),
- PIK3CA (p.E545K, p.H1047R),
- ERBB2 (p.Y772_A775dup).
These mutations are critical for guiding personalized therapies, including targeted treatments for BRAF, KRAS, PIK3CA, and AKT1 mutations. The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product plays an integral role in advancing cancer diagnostics and improving the accuracy of liquid biopsy testing, facilitating the development of more effective cancer treatments.
- Comprehensive Mutation Coverage: Includes mutations in AKT1, BRAF, KRAS, PIK3CA, and ERBB2.
- High-Quality Control Material: Serves as a positive control for digital PCR and NGS.
- Versatile Applications: Ideal for developing and validating sequencing protocols.
- Enhanced Personalized Treatment: Facilitates the identification of mutations linked to effective therapies.
The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product from SensID is a highly specialized and essential tool for liquid biopsy assays, widely used in both diagnostic and research settings. This product is specifically designed to target a selection of crucial genetic mutations, which are often implicated in a variety of cancers, including lung, breast, colorectal, and melanoma. The mutations included in this multiplex are AKT1, BRAF, KRAS, PIK3CA, and ERBB2, all of which play significant roles in cancer development and therapeutic decisions.
The 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product contains these mutations at a 0.1% allelic frequency (AF), providing a valuable positive control standard for critical applications like digital PCR and next-generation sequencing (NGS). It is an indispensable tool for validating and developing sequencing protocols such as Whole Genome Sequencing (WGS), Amplicon Sequencing, and PCR protocols. Additionally, this product is ideal for determining the detection limits of various methods and ensuring high-confidence variant calling, which is crucial for the accuracy of genomic analyses.
The specific mutations featured in the 5-Gene-Multiplex 0.1% AF cfDNA in Plasma include:
- AKT1 (p.E17K),
- BRAF (p.V600E),
- KRAS (multiple variants),
- PIK3CA (p.E545K, p.H1047R),
- ERBB2 (p.Y772_A775dup).
These mutations are directly linked to important targeted therapies. For example, BRAF mutations, such as p.V600E, are associated with treatment options like vemurafenib, while KRAS mutations play a crucial role in the efficacy of cetuximab therapy. Similarly, mutations in PIK3CA and AKT1 also guide personalized treatment choices for patients.
With its ability to simulate real-world genetic variability, this 5-Gene-Multiplex 0.1% AF cfDNA in Plasma product ensures that diagnostic assays, especially those used in liquid biopsy testing, deliver precise and reliable results, which are essential for the development of personalized cancer therapies.
5-Gene-Multiplex 0.1% AF cfDNA in Plasma
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Frequently paired with this kit
Other assays and instruments lab teams add alongside the 5-Gene-Multiplex 0.1% AF cfDNA in Plasma.
Plasma 1x (Human-Tech) DNA Free 40 ml
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
